The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Finncap have a 25p target based upon the existing business, with nothing at all for COVID-19.
The current m/cap is largely covered by the valuation for the extremely profitable Food Intolerance division. Then you've got CD4, which alone could be worth multiples of the current share price, plus the allery testing division. Both of these are almost in the current m/cap for free imo (and Finncap's).
You really need to read Finncap's research to realise the upside from the imminent CD4 testing.
Today's COVID-19 news is entirely a bonus on top of that existing business.
Finncap have a 25p target based upon the existing business, with nothing at all for COVID-19.
The current m/cap is largely covered by the valuation for the extremely profitable Food Intolerance division. Then you've got CD4, which alone could be worth multiples of the current share price, plus the allery testing division. Both of these are almost in the current m/cap for free imo (and Finncap's).
You really need to read Finncap's research to realise the upside from the imminent CD4 testing.
Today's COVID-19 news is entirely a bonus on top of that existing business.
Many thanks for the info
It may never get to market. The are yet to develop the test. If they do it will leap. If it proves to be accurate then there is no upward limit that I would even think of hazarding a guess at.
Because these things can take days to months to get from one stage to the next and someone else might get there first, so right now ODX is a punt. A cheap one to be sure but risky if you are thinking it is going to rescue a portfolio from the last 2 months losses. I will not be putting a lot of funds into. It's on my watchlist for sure and I might even slip a few quid in to keep my interest up but it's very wait and see territory. Fingers crossed it delivers because it's got the potential to be huge. GLA
How long to get this to the market? ?
If you think what ncyt did on covid 19 test. Where only a small amount of population needed testing.
Then look at the antibody test. You would have to pretty much test everyone.
It will probably come to the point where you can't go about normal business without having a test . To see if you are immune.
Media will be covering this, given it's a UK government backed initiative. Expect lots more interest here over the coming days. An effective antibody test is crucial and the potential here for ODX is huge.